

First author, Trial abbreviation, year	Age (years)		Male (%)		CHA2DS2-VASc scores		HTN (%)		DM (%)		CAD (%)		Anticoagulation (%)		Baseline episodes of pAF		LVEF (%)		LA size (mm)	
	Ablation group	AAD group	Ablation group	AA D group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group	Ablation group	AAD group
Andrade, EARLY-AF, 2020 [18]	57.7±12.3	59.5±10.6	72.7%	68.5%	Mean 1.9±1.0	Mean 1.9±1.1	37%	36.9%	N/A	N/A	7.8%	4.7%	Warfarin 3.2%, Non–vitamin K antagonist 63.6%	Warfarin 6.0%, Non–vitamin K antagonist 58.4%	Median 3/month (1-10)	Median 3/month (1-10)	Mean 59.6±7.0%	Mean 59.8±7.6%	Mean 39.5±5.0 mm	Mean 38.1±6.5 mm
Morillo, RAAFT-2, 2014 [10]	56.3±9.3	54.3±11.7	77.3%	73.8%	Mean 0.5±0.7	Mean 0.7±0.8	42.4%	41.0%	1.5%	6.6%	9.1%	3.3%	53.0%	31.1%	Median 10 in the past 6 months (5-40)	Median 10 in the past 6 months (4-40)	Mean 61.4±4.8%	Mean 60.8±7.0%	Mean 40±5 mm	Mean 43±5 mm
Neilson, MANTRA-PAF, 2012 [11]	56±9	54±10	68%	72%	≥2:18.4%	≥2:19.6%	29%	36%	4%	7%	4%	1%	N/A	N/A	N/A	N/A	40-60%: 19.8%, >60%: 79.4%	40-60%: 17.5%, >60%: 81.7%	Mean 40±6 mm	Mean 40±5 mm
Wazni, RAAFT-1, 2005 [12]	53±8	54±8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Mean duration 5±2 months	Mean duration 5±2.5 months	Mean 53±5%	Mean 54±6%	Mean 41±8 mm	Mean 42±7 mm
Wazni, STOP AF First, 2020 [19]	60.4±11.2	61.6±11.2	61%	58%	≥2:55%	≥2:55%	56%	58%	14%	17%	12%	12%	69%	69%	N/A	N/A	Mean 60.9±6.0%	Mean 61.1±5.9%	Mean 38.7±5.7 mm	Mean 38.2±5.4 mm

Table 2: Basic characteristics of study participants